Posted February 16, 2017
In an interview with the Journal of the American Medical Association (JAMA), Drs. Rudy Tanzi and Berislav Zlokovic of the Cure Alzheimer’s Research Consortium discuss why recent drug trials produced less-than-promising results, and why they are optimistic about the future of the field. Tanzi explains how one drug was given to patients too late in the disease process – if administered earlier in the disease, it may have had a disease-modifying effect.
Tanzi and Zlokovic also describe how their own research on topics like infection and brain vasculature are helping to develop a more complete understanding of Alzheimer’s and identify new targets for intervention.
February 16 2017
March 23 2015
November 7 2014